NextConsensus
Discuss a Program

Who uses it

Five teams. One question: which claims are becoming harder for institutions to ignore?

All five reconstruct the same thing by hand — first appearance, wording changes, evidence attached, whether a claim held or spread. We run it across a therapeutic area and rank what it turns up.

Buyer use cases

What each team can answer.

Competitive Intelligence

  • Which competitor benefit claims are gaining support and spreading?
  • Is a disputed positioning claim stabilising across independent sources?

Respond while the shift is forming, not once it is priced in.

Medical Affairs & Evidence Strategy

  • Which claims about your drug are losing qualifiers and hardening?
  • Which remain contested, and where is the evidence not keeping up?

Plan evidence against where the record actually sits.

Drug Safety & Pharmacovigilance

  • Which adverse-event claims are persisting through multiple revisions?
  • Is a previously dismissed concern being reintroduced?

Escalate on the record, not on the first formal notice.

Business Development & Diligence

  • Was the current consensus recent or durable — and was it contested?
  • Are the claims that matter still moving, or have they settled?

Price the asset on how settled its record is.

Market Access & Regulatory Strategy

  • Where is public representation running ahead of formal policy?
  • Is authority language appearing in public sources before formal action?

Start scenario work while the gap is still open.

Against your own calendar · Illustrative

Where it lands against the deadline you already have.

Your milestones, not ours. How much warning a claim affords is not something we can promise.

12 months out · Illustrative Evidence gaps
  • Point RWE work at the claims that are moving
  • Brief KOLs before guideline drafting opens
6 months out · Illustrative Dossier and committee prep
  • Answer persisting claims in P&T dossiers
  • Align regional teams on converging authority language
3 months out · Illustrative Rapid response
  • File formulary packages with the evidence attached
  • Draft field responses for the contested claims only

Regional coverage

Mapped to regional authority frameworks.

Claims are structured against the bodies that decide in each market.

United States

FDA · CMS · NCCN · ICER

United Kingdom

NICE · MHRA · NHS England

European Union

EMA · EU JCA · National HTA Bodies

Canada

CADTH / CDA · INESSS · Health Canada

Australia

PBAC · TGA · MSAC

Japan

PMDA · MHLW · Chuikyo